摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-Pyridinyl)-2-(2,3,6-trifluorophenyl)ethanone | 1228788-33-7

中文名称
——
中文别名
——
英文名称
1-(2-Pyridinyl)-2-(2,3,6-trifluorophenyl)ethanone
英文别名
1-pyridin-2-yl-2-(2,3,6-trifluorophenyl)ethanone
1-(2-Pyridinyl)-2-(2,3,6-trifluorophenyl)ethanone化学式
CAS
1228788-33-7
化学式
C13H8F3NO
mdl
——
分子量
251.208
InChiKey
TVOCTWRFIGGZCY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    30
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    申请人:Brockunier Linda L.
    公开号:US20110218202A1
    公开(公告)日:2011-09-08
    Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.
    公式I的化合物能够调节体内环状鸟苷酸单磷酸(“cGMP”)的产生,一般适用于治疗和预防与cGMP平衡紊乱相关的疾病。此外,本发明还涉及制备公式I化合物的过程,以及它们用于治疗和预防上述疾病和制备药物的用途,以及包含公式I化合物的制药制剂。
  • US8741910B2
    申请人:——
    公开号:US8741910B2
    公开(公告)日:2014-06-03
  • [EN] SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE
    申请人:MERCK SHARP & DOHME
    公开号:WO2010065275A1
    公开(公告)日:2010-06-10
    Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.
  • 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP2373317B1
    公开(公告)日:2016-12-14
查看更多